Results 181 to 190 of about 88,199 (267)

Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis

Journal of Internal Medicine, Volume 299, Issue 6, Page 741-753, June 2026.
Abstract Objectives To investigate, in early rheumatoid arthritis, whether bridging with glucocorticoids (GCs) is associated with an increased risk of flare following GC tapering and withdrawal. Methods A total of 810 NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD‐STAR) patients were included in this post hoc analysis: all received ...
Kristina Lend, Jos W. R. Twisk, Frieda A. Koopman, Anna Rudin, Merete Lund Hetland, Till Uhlig, Dan C. Nordström, Michael T. Nurmohamed, Bjorn Gudbjornsson, Kim Hørslev‐Petersen, Marte Schrumpf Heiberg, Tuulikki Sokka‐Isler, Gerdur Grondal, Espen A. Haavardsholm, Mikkel Østergaard, Jon Lampa, Ronald van Vollenhoven   +16 more
wiley   +1 more source

Immunosuppressive Medications and Nonserious Infections in People With Rheumatoid Arthritis: A Prospective Cohort Study

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective People with rheumatoid arthritis (RA) are at increased risk of serious infection, but less is known about nonserious infections. Our prospective cohort study evaluated associations between medications for RA and the risk of nonserious infections.
Michael D. George, Kelly Gavigan, Shilpa Venkatachalam, David Curtis, Laura Stradford, W. Benjamin Nowell, Joshua F. Baker, Fenglong Xie, Jeffrey R. Curtis   +8 more
wiley   +1 more source

Evolution of therapy for autoimmune diseases in pregnancy: a retrospective study from 2000 to 2023. [PDF]

Front Med (Lausanne)
Garufi C, Rizzo F, Matys V, Garufi E, Botta A, Andreozzi V, Salvi S, Ghi T, De Carolis S.   +8 more
europepmc   +1 more source

Integrative Analyses Identify a cGAS‐STING Pathway‐Driven Signature With Context‐Dependent Roles in Systemic Lupus Erythematosus

Advanced Science, Volume 13, Issue 25, 4 May 2026.
Zhang et al. identify M7core, a critical cGAS‐STING pathway‐driven gene signature that is activated in most lupus patients’ blood and links to lupus disease severity, lymphopenia, and lupus nephritis. They further reveal the diagnostic and pathogenic characteristics of M7core and emphasize the importance of assessing pathway activity before initiating ...
Lele Zhang, Ming‐Ju Amy Lyu, Ze Hong, Jing Sun, Lan Guo, Jiameng Hu, Munire Maimaiti, Chenhui Li, Jinyi Song, Xiang Zhang, Huansha Yu, Chen Wang, Xuan Wang, Haiyang Hu   +13 more
wiley   +1 more source

Progressive Fibrosis in Hydroxychloroquine Cardiomyopathy Mimicking Hypertrophic Cardiomyopathy and Cardiac Amyloidosis. [PDF]

JACC Case Rep
Altaha Z, Zhao X, Wang Y, Fine N, Kiamanesh O, Miller RJH.   +5 more
europepmc   +1 more source

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring

Arthritis &Rheumatology, Volume 78, Issue 5, Page 1102-1113, May 2026.
Objective Using a hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust the HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg, Benoît Blanchet, Yann Nguyen, Fauzia Hollnagel, Ada Clarke, Michelle Petri, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald F. Van Vollenhoven, Cynthia Aranow, Véronique Le Guern, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Søren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Julie Chezel, Alicja Puszkiel, Nathalie Costedoat‐Chalumeau   +42 more
wiley   +1 more source

Lupus erythematosus-specific bullous lesions: A case report. [PDF]

Medicine (Baltimore)
Li S, Zhang M, Nie Y, Yang X.
europepmc   +1 more source

Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome

Arthritis &Rheumatology, Volume 78, Issue 5, Page 1124-1133, May 2026.
Objective Antiphospholipid syndrome (APS) is a thromboinflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)–positive patients using whole‐blood transcriptomics.
Amala Ambati, Feiyang Ma, Katarina Kmetova, Sherwin Navaz, Claire K. Hoy, Cyrus Sarosh, Ajay Tambralli, Erika Navarro‐Mendoza, Johann E. Gudjonsson, J. Michelle Kahlenberg, Jacqueline A. Madison, Alí Duarte‐García, Jason S. Knight, Yu Zuo   +13 more
wiley   +1 more source

Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up. [PDF]

Rheumatology (Oxford)
Michelakis IE, Kapsia E, Boletis JN, Marinaki S, Sfikakis PP, Tektonidou MG.   +5 more
europepmc   +1 more source

Stanniocalcin 2‐Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK/Beclin 1 Signaling

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are effective in treating NSCLC with EGFR mutations, the development of resistance limits their long‐term efficacy. Autophagy has been implicated as a potential mechanism behind this acquired resistance.
Yi‐Nan Liu, Yi‐Ling Chen, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, Tzu‐Hsiu Tsai, Jin‐Yuan Shih   +6 more
wiley   +1 more source